Pay(or) Attention, Drug and Device Makers: FDA’s New Guidance for Talking to Health Plans - afslaw.com
FDA issued new guidance on manufacturer communications with health plans regarding unapproved uses of approved drugs/devices, potentially affecting promotional practices.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that communicate with health plans about their products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the change text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA released new guidance clarifying permissible communications with health plans about unapproved uses of approved products, potentially altering promotional boundaries.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that communicate with health plans about their products.
What you must do
Review the new guidance and assess current communications with health plans for compliance with updated FDA expectations.
Deadline
Not specified in the change text.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA warning letter flags serious violations at New Jersey manufacturing facility for GLP-1 weight loss jabs - cleanroomtechnology.com
- FDA issues warning letter after GLP-1 manufacturer refuses inspectors access - biospace.com
- Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars - biospace.com
- What to Know About the FDA’s Recent Decision to Allow Florida to Import Prescription Drugs from Canada - kff.org
- DOJ prohibits Arizona company from distributing adulterated or misbranded supplements - NutraIngredients.com